Clinical trials: Metastatic Colorectal Cancer (MCRC)
Metastatic Colorectal Cancer
Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated…
- Trial name
- ELEVATE CRC (NCT05330429)
- Testing
- Magrolimab, Bevacizumab, Irinotecan
- Where
- 51 sites in United States, Australia and 8 more
- Volunteers
- 77 people
- Sponsor
- Gilead Sciences
Metastatic Colorectal Cancer, Colorectal Cancer
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.
- Trial name
- NCT01507545
- Testing
- MORAb-004, Best supportive care
- Where
- 67 sites in United States
- Volunteers
- 154 people
- Sponsor
- Morphotek
Metastatic Colorectal Carcinoma (mCRC), Metastatic Liver Cancer
Streamlining Radioembolization for CCC and Metastatic Liver Cancer
TARE uses radioactive microspheres (20-60 μm), which are trapped in tumors due to abnormal vasculature, while normal liver sinusoids (≤15 μm) prevent their passage.
- Conditions
- Metastatic Colorectal Carcinoma (mCRC), Metastatic Liver Cancer, Cholangiocarcinoma
- Trial name
- ISTAR-03 (NCT07043387)
- Where
- 4 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Colorectal Cancer
A Study in Second Line Metastatic Colorectal Cancer
The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.
- Trial name
- NCT01183780
- Testing
- Ramucirumab, Irinotecan, Folinic Acid
- Where
- 213 sites in United States, Argentina and 24 more
- Volunteers
- 1,072 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)
National multicentric phase II trial evaluating whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients with KRAS and NRAS wild-type genes, assessed…
- Trial name
- TIME (NCT02404935)
- Testing
- Cetuximab, FOLFIRI and cetuximab
- Where
- 47 sites in France
- Volunteers
- 139 people
- Sponsor
- UNICANCER
Metastatic Colorectal Cancer
Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
Regorafenib has been proved to improved survival in patients with metastatic colorectal cancer who have been failed to all of known standard chemotherapy (The CORRECT study).
- Trial name
- NCT01786538
- Testing
- Regorafenib/FOLFOX
- Where
- South Korea
- Sponsor
- Asan Medical Center
Metastatic Colorectal Cancer
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine whether SCT200 is safe and tolerant in the treatment of metastatic colorectal cancer
- Trial name
- NCT02211443
- Testing
- Recombinant full human Anti-EGFR Monoclonal Antibody
- Volunteers
- 21 people
- Sponsor
- Sinocelltech Ltd.
Colon Adenocarcinoma, ERBB2 Gene Amplification
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it…
- Conditions
- Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma
- Trial name
- NCT03365882
- Testing
- Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- SWOG Cancer Research Network
Cachexia; Cancer, Cachexia
Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm).
- Conditions
- Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC)
- Trial name
- REACH (NCT07888075)
- Testing
- Rilogrotug
- Volunteers
- 950 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Metastatic Colorectal Cancer
Cetuximab for Elderly Patients With mCRC
OBJECTIVE: The objective of the trial is to judge on the benefit obtained by an upfront cetuximab treatment delivered as monotherapy or as part of a combination treatment with capecitabine in vulnerable elderly patients selected…
- Trial name
- NCT01718808
- Testing
- Cetuximab, Capecitabine
- Where
- 14 sites in Switzerland
- Volunteers
- 24 people
- Sponsor
- Swiss Cancer Institute
Metastatic Colorectal Cancer (mCRC)
A Clinical Study of Arfolitixorin in Patients With mCRC
This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 90 people will participate in the study.
- Trial name
- NCT06922383
- Testing
- Arfolitixorin, Leucovorin
- Where
- 3 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Isofol Medical AB
Metastatic Colorectal Cancer (mCRC)
Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (REACH)
The primary objective of this trial is to compare the effects of 18 weeks structured exercise training versus on control on healt-related quality of life in patients with mCRC undergoing first-line chemotherapy.
- Trial name
- REACH (NCT06938971)
- Testing
- Exercise training
- Where
- 4 sites in Denmark
- Volunteers
- 150 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Metastatic Colorectal Cancer
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
In mCRC, response to second-line chemotherapy is limited, and few treatment options are available. It is urgent to design an optimal second-line treatment regimen to improve the response rate and prolong the survival of patients…
- Trial name
- NCT06202001
- Testing
- Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
The study is an double blind, randomized, multicenter phase 3 trial. The efficacy analyses are based on 570 Chinese patients with RAS wt mCRC treated with mFOLFOX-6 ± cetuximab.
- Trial name
- NCT03426371
- Testing
- KL-140
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)
The purpose of this study is to evaluate the safety of treatment with Eye90 microspheres in patients with unresectable Hepatocellular Carcinoma (HCC) and metastatic Colorectal Cancer (mCRC).
- Conditions
- Hepatocellular Carcinoma Non-resectable, Metastatic Colorectal Cancer, Liver Cancer
- Trial name
- NCT04926376
- Testing
- Eye90 Microspheres
- Where
- New Zealand
- Volunteers
- 8 people
- Sponsor
- ABK Biomedical
Metastatic Colorectal Cancer
Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)
The primary objective of this study is to investigate the anti-angiogenic effect of bevacizumab measured by CTP as a predictive marker for efficacy measured by progression-free survival (PFS) in mCRC patients under first-line…
- Trial name
- AVA-CTP (NCT02511756)
- Testing
- Computed tomography X-ray system
- Where
- 5 sites in Switzerland
- Volunteers
- 50 people
- Sponsor
- Patrick Veit-Haibach
Colorectal Cancer Metastatic
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC
This study is a phase II study to evaluate the efficacy, safety and tolerability of HLX26 and HLX10 in the treatment of patients with metastatic colorectal carcinoma that had received 3 prior therapies.
- Trial name
- NCT05584137
- Testing
- HLX26, HLX10
- Where
- 2 sites in China
- Volunteers
- 2 people
- Sponsor
- Shanghai Henlius Biotech
Colorectal Cancer
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC.
- Trial name
- MODUL (NCT02291289)
- Testing
- Cetuximab, FOLFOX induction regimen, Fluoropyrimidine (5-FU/LV or capecitabine)
- Where
- 154 sites in Argentina, Belgium and 21 more
- Volunteers
- 1,044 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer (mCRC)
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX…
- Trial name
- NCT02069704
- Testing
- Bevacizumab biosimilar (BEVZ92), Avastin® (bevacizumab, reference product)
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- mAbxience Research S.L.
Colorectal Cancer
TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
The purpose of this study: To explore the comparative effectiveness of BIBF 1120 in terms of : Progression-free survival (PFS), objective response, overall survival Evaluate and compare safety
- Trial name
- AIO-KRK-0111 (NCT01362361)
- Testing
- mFOLFOX6 + BIBF 1120
- Where
- 12 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg